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Background: Toxoplasmosis is caused by infection with the protozoan parasite Toxoplasma gondii. Acute infections
in pregnant women may be transmitted to the fetus and cause severe illness. The purpose of this study was to
establish a dedicated surveillance network (DSN) for congenital toxoplasmosis (CT) in Greece, in order to assess the
birth prevalence of CT.
Methods: A DSN of thirty clinicians was established for reporting CT cases from hospitals throughout Greece. The
clinicians were selected on the basis that there was a high possibility the suspected cases would be referred to
them from district hospitals or private clinics. Suspected cases of CT were reported on a monthly basis with a zero
reporting card during a surveillance period from April 2006 to December 2009. A questionnaire was sent for any
suspected case to record information including demographic parameters, clinical signs and symptoms and
laboratory results. Serological and molecular confirmation of cases was performed by the Pasteur Hellenic Institute.
All newborns suspected of CT received treatment and were serologically and clinically followed up for one year.
Results: The monthly response rate reached 100%, although only after reminders sent to 65% of the participant
physicians. Sixty-three suspected CT cases were recorded by the DSN during the study period including fourteen
confirmed and seven probable cases. Ten cases (47.6%) presented with symptoms at birth. Chorioretinitis was the
most prominent manifestation, occurring in five symptomatic CT cases (50%). No other symptoms appeared by the
end of the one year clinical follow up. No case was recorded by the existing surveillance system of the Hellenic
Center of Disease Control and Prevention (HCDCP) during the same time period. Birth prevalence was estimated at
0.45, 0.51 and 0.51 per 10,000 births for 2007, 2008 and 2009 respectively. The incidence rate of symptomatic CT at
birth was estimated at 0.10 cases per 10,000 births per year in Greece (for the period 2007–2009).
Conclusion: The DSN for CT proved to be more sensitive than the classical notification system, easy in application
and very efficient in reporting rare diseases such as CT. Similar DSNs could be used to provide useful information
on other rare diseases.
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Toxoplasmosis occurs worldwide and is one of the most
common parasitic infections [1]. When primary infec-
tion occurs during pregnancy, the parasite can be trans-
mitted from the mother through the placenta to the
fetus. Congenital infection is usually asymptomatic, but
when symptomatic it may cause neurological or visual
impairment or even death [2].
Strategies for the prevention of congenital toxoplas-
mosis depend largely on the incidence of the disease.
Several surveillance schemes have world widely been
implemented for reporting CT cases in order to assess
the incidence of CT. In USA, information on the CT in-
cidence was derived from the neonatal screening pro-
gram by the New England Regional Toxoplasmosis
Working Group, which showed an estimated incidence
ranging from 0.1 to 1 per 1000 live births in different
areas [3]. In Europe, there is a high heterogeneity between
countries in the surveillance of the disease. Available data
on the burden of CT provided by epidemiological surveys
are limited in number and validity. A survey conducted
within the EUROTOXO project in 2004 among 28
European countries revealed that only 14 had a surveil-
lance system for toxoplasmosis (congenital or not).
Denmark, France, Germany, and Italy (the latter only at
regional level), were the only participating European
countries who had implemented a surveillance system
that was specifically dedicated to CT and that was able
to detect symptomatic as well as asymptomatic cases
[4]. Systems which survey toxoplasmosis in the general
population are of least interest because it is impossible
to distinguish congenital from acquired toxoplasmosis
without data on the serological status at birth [5]. Fur-
thermore, the vast majority of acquired Toxoplasma
gondii infections in immunocompetent individuals are
benign and the proportion of asymptomatic cases is
estimated to be 70% [6].
CT has been a notifiable disease in Greece since 2004
and subject to continuous data collection by the
HCDCP. The health event under surveillance is toxo-
plasmosis (congenital or not), as defined by the Euro-
pean Commission decision (symptomatic toxoplasmosis
cases serologically confirmed) [7].
The aim of the study was to apply a DSN for CT, in
order to assess the birth rate of CT in Greece including
asymptomatic cases and also to compare it to the exist-
ing notification system, which is based only on symp-
tomatic CT.
Methods
Ethics and consent statement
This study was approved by the ethics committee of the
Medical Faculty of the University of Thessaly. The doc-
tors who participated in the study informed the parentsabout the purpose of the study and obtained verbal
consent.
The network was established within the Greece-
Cyprus Pediatric Surveillance Unit (GCPSU), which has
been a member of the International Network of Pediatric
Surveillance Units since 2002.
Establishment of network-population under surveillance
The GCPSU supervised and managed this study over the
period from April 2006 to December 2009. Specifically,
in April 2006 the Unit decided to implement a new ac-
tive surveillance scheme for the detection of CT cases,
based on a group of selected clinicians, who were able to
diagnose the disease at different stages. The Toxoplas-
mosis Study Group (TSG) was established including
thirty clinicians of different specialties (18 pediatricians,
7 neonatologists, 3 ophthalmologists, 2 neurologists)
from different geographical regions covering the whole
of Greece. The network was based mostly on secondary
and tertiary health care university hospital experts, as it
was presumed that cases of CT from district hospitals or
private clinics would most probably be referred to uni-
versity hospitals for diagnosis and treatment. One person
from each registered hospital was defined as the focal
point of the study and was responsible for reporting any
suspected case. The network was initially established in
the District of Thessaly in Central Greece, under the
supervision of the Laboratory of Hygiene and Epidemi-
ology of the University of Thessaly.
Regular notification of CT cases commenced in Janu-
ary 2007, when the network covered almost 86% of the
population of children (Districts of Thessaly, Macedonia,
Thrace, Peloponnesus, Sterea Hellas and Attica),
whereas by January 2008 it reached approximately 95%
of the Greek pediatric population (including the Districts
of Crete and Epirus). We assume the actual coverage
was more than 97% of the pediatric population, as
patients in remote areas (i.e. the Aegean and the Ionian
Islands) are usually referred to hospitals in metropolitan
cities.
Reporting system based on active surveillance
Reporting was based on monthly cards (including ze-
ro reporting). Clinicians were supplied with monthly
reporting cards and were asked to report any suspected
case that met the reporting criteria. Cards were faxed or
e-mailed to the Laboratory of Hygiene and Epidemi-
ology, where data were gathered and entered into a data-
base. The scientific coordinator of the study was
responsible for identifying duplicate reports. Clinicians
were reminded (by phone or e-mail) at the beginning of
the next calendar month if a monthly report was not
received. When a suspected case was reported, a ques-
tionnaire was sent to the reporting clinician to obtain
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mother’s medical history, and laboratory and imaging
results of the patient, physical examination and treat-
ment). Personal contact details of the patients were kept
on a separate sheet of the questionnaire by the coordi-
nator to ensure protection of personal data. Samples of
all patients were sent to the Pasteur Hellenic Institute,
which was used as the reference laboratory for confirm-
ation of suspected cases.Case definitions
Clinicians were asked to report any newborn or infant
≤12 months old (after this age IgM or IgA may reflect
acquired infection) or stillbirth in whom CT was
suspected.
The criteria for suspected CT included detection of
Toxoplasma- specific IgM IgA, and IgG antibodies, or
presentation of hydrocephalus, intracranial calcifica-
tions, microcephaly, retinitis, micropthalmia, unex-
plained lymphadenopathy and hepatosplenomegaly in
infancy.
A probable case of CT was defined as a child <12 months
of age with unexplained hepatosplenomegaly or lymph-
adenopathy or any symptom of the classical triad (hydro-
cephalus, intracranial calcifications and chorioretinitis) and
the presence of Toxoplasma IgG antibodies, with maternal
serological results compatible with confirmed infection du-
ring pregnancy) or any asymptomatic infant <12 months of
age with high levels of Toxoplasma IgG (>300 IU /ml) and
maternal serology compatible with Toxoplasma infection
during pregnancy.
A confirmed case of CT (asymptomatic or not) was
diagnosed either by the demonstration of Toxoplasma in
body tissues or fluids, and/or the detection of Toxo-
plasma nucleic acid in a clinical specimen, and/or the
Toxoplasma specific antibody response (IgM, IgG, IgA)
in a newborn, and/or the persistently stable IgG Toxo-
plasma titre in an infant up to 12 months of age [8].
However, if the child has been treated continuously
with sulfadiazine and pyrimethamine, the synthesis of
Toxoplasma-specific IgG antibodies can be suppressed,
and the serological confirmation of the infection cannot
be made with certainty [9].Estimation of birth prevalence-denominators
The birth prevalence of CT (per 10,000 live births per
year) for the specific study period was estimated by the
number of newborns with confirmed or probable disease
divided by the number of births in Greece (84,032 births
during the period April-December 2006, 111,926 births
in 2007, 118,302 births in 2008 and 117,933 births in
2009 respectively).Results
By December 2009, 1320 cards had been collected by
the Unit. Response rate reached 100% during the surveil-
lance period. On average, monthly reminders were sent
to 65% of the reporting clinicians.
A total of 85 cases were reported during the study
period. Specifically, 43 cases were reported by pediatri-
cians, 39 by neonatologists, and 3 by ophthalmologists,
whereas no case was initially reported by neurologists.
Most reports were sent by hospitals in metropolitan
areas revealing the fact that patients usually are referred
to tertiary health care centres (university hospitals) for
treatment and follow up. Seven of the 85 reported cases
did not fulfill the inclusion criteria as they were older (3
probable CT cases presenting with chorioretinitis and 4
possible acquired toxoplasmosis cases). Another 7 cases
were reported by more than one source providing infor-
mation on different clinical stages o f the same patient.
Finally, in 8 reported cases no further information was
provided because of parents’ refusal or emmigration. A
total of 22 reported cases were thus excluded from the
study. The remaining 63 reported cases which were con-
sidered as suspected CT included 34 boys (54.0%), 28
girls (44.4%), and one stillborn child. Thirty-three
(52.4%) patients were Greek, while 30 (47.6%) immi-
grants (Albanians, Russians, and Bulgarians) and local
Roma. They were all born in Greek neonatal depart-
ments by mothers living the last five years in Greece and
none of the mothers had travelled abroad during
pregnancy.
In total, the 63 suspected CT cases included 14 con-
firmed and 7 probable cases. More specifically, 9 con-
firmed and 4 probable CT cases were reported by
pediatricians, 5 confirmed and 3 probable CT cases by
neonatologists (Table 1). Age-wise, the cases included 17
children aged 0–3 months and 4 children aged 4–12
months. Eight patients were Greek (38.1%), 7 were Alba-
nian (33.3%), 3 were local Roma (14.3%), 1 from Bulgaria
(4.8%) and 2 (9.5%) from the former Soviet Union.
Eleven of the cases (64.7%) presented with no symptoms
at birth.
All newborns were regularly followed up both clinic-
ally and serologically until the first year of age (at this
point no interference from the coordinator of the study
was done for the treatment and follow up by the report-
ing clinicians). Clinical evaluation included pediatric,
neurological and ophthalmological assessment.
Among the 21 confirmed and probable cases, 7
patients (33.3%) presented a severe form of the disease,
including 3 patients with bilateral chorioretinitis and
intracranial calcifications, and one case each of multiple
intracranial calcifications and hypertonia; hydrocephalus
and bilateral chorioretinitis; microcephaly, dilatation of
ventricles and intracranial calcifications; and of bilateral
Table 1 Classification of suspected, confirmed and probable cases according to the reporting source
Number of participants C.T. reported C.T. suspected C.T. confirmed C.T. probable
Neonatologists 7 39 39 5 3
Pediatricians 18 43 24 9 4
Ophthalmologist 3 3 0 0 0
Neurologists 2 0 0 0 0
Total 30 85 63 14 7
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lesions or signs included hepatosplenomegaly, rash,
jaundice, hypertonia or hypotonia. The majority of cases
(80.9%) were diagnosed during the first month of life
(mean age at diagnosis 20 days), as a result of serological
examinations of newborns born to mothers with a his-
tory of toxoplasmosis during pregnancy. The clinical fol-
low up of children for one year did not reveal any
further new symptoms.
According to the presented data, the birth prevalence
of CT was approximately 0.45 cases per 10,000 births in
2007, 0.51 per 10,000 in 2008 and 0.51 per 10,000 in
2009 (Table 2). The incidence rate of symptomatic CT at
birth was estimated at 0.10 cases per 10,000 births per
year in Greece (for the period 2007–2009).
In contrast to the results of the DSN, no cases were
reported by private physicians or hospital clinicians du-
ring the three year period with the notification system of
the HCDCP. Looking for cases during the previous years,
only two cases of symptomatic CT were reported to the
HCDCP between 2004 and 2006 (provided by HCDCP).
Discussion
The DSN for CT managed to identify fourteen con-
firmed cases and seven probable cases during the study
period. No case was reported to the mandatory notifica-
tion system of the HCDCP for the same time period.
Surveillance of CT with the current system of the
HCDCP has been in existence since 2004 based only on
case definitions of symptomatic CT.
Notification in Greece is based strictly on the clinician.
The heavy scheduled program of most doctors and theirTable 2 Classification of suspected, probable and confirmed c
2009, Greece
Suspected cases Confirmed
April 2006-December 2006 9 2
January 2007-ecember 2007 21 2
January 2008-December 2008 17 5
January 2009-December 2009 16 5
Total 63 14
*Confidence intervals based on the Poisson distribution.
**This corresponds to a period of 9 months (April-December).belief that surveillance is time-consuming are factors
leading to defects in the reporting system. In previous
studies in other countries, underreporting of diseases
was attributed to ignorance about the requirements or
methods of reporting, including not knowing which dis-
eases are required to be reported, not knowing how a
disease should be reported, concerns regarding confiden-
tiality and perceptions that the list of reportable diseases
is too extensive [10-13].
However, the DSN succeeded in collecting an adequate
number of reports by using a small number of clinicians
from various disciplines who collaborated under the
same spectrum of cases of CT. A very small number of
the reports were duplicated (sent both by neonatologists,
pediatricians and ophthalmologists) also revealing the ef-
fectiveness of cross matching, hence reducing the pos-
sibility of missing any case. A laboratory surveillance
network was set up, by the name ToxoSurv, in
France in 2006 based on a network of specialized la-
boratories certified in prenatal and neonatal diagnosis
of toxoplasmosis. The system provided more robust
and reliable results due to the exhaustive process
adopted for notification (all laboratories carrying out
the diagnosis in France were invited to participate in
the surveillance) [14]. In our study, one reference la-
boratory (the Hellenic Pasteur Institute) was used to
carry out the confirmation of suspected cases, either
by serological or PCR techniques, to avoid differ-
ences in methods used by laboratories of the selected
hospitals.
Response rate was quite high throughout the period of
surveillance, but required reminding through telephoneases during the study period April 2006 to December
cases Probable cases Birth prevalence
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contact proved to be efficient and cost-effective (invol-
ving one-person part-time job) in a small country like
Greece. Both the e-mail based reminding system and the
web-based reporting system proved simple, flexible and
minimized paperwork.
In our study the prevalence of CT was estimated with-
out taking into consideration the number of induced
abortions or terminations of pregnancy after prenatal
diagnosis of CT and this could be a reason for underesti-
mating the true birth prevalence of CT in Greece. To
overcome this limitation in the future, we believe that a
network of pediatricians, neonatologists and obstetri-
cians would be an ideal combination to study the epi-
demiology of uncommon birth disorders in Greece.
Another reason why our data may be an underestimate
of the true prevalence of CT in Greece involves adminis-
tration of treatment to infected pregnant women and
their neonates, which could have affected both the num-
ber of confirmed cases and the proportion of sympto-
matic ones.
Compared to epidemiological data in other countries,
the birth prevalence of CT in Greece seems much lower
than in the European countries involved in the EURO-
TOXO project (Bénard A, Salmi LR, Mouillet E: System-
atic review on the burden of congenital toxoplasmosis
in Europe, unpublished), particularly Sweden. It should
be noted, however, that the EUROTOXO data were
largely collected before 2000. According to the EURO-
TOXO results, in Austria the birth prevalence of CT
was estimated at approximately 7.4 per 10,000 births
[15], in Denmark at 3 per 10,000 births [16], in Germany
at 13 per 10,000 births [17], in Poland at 11.3 per
10,000 births [18], in Sweden at 0.73 per 10,000
births [19], in Switzerland at 5 per 10,000 births [20]
and in Italy (on a regional level) 13.8 per 10,000
newborns [21]. The incidence of symptomatic CT
observed in our study was comparable to those observed
in England and Ireland between 2002 and 2004 (0.16
[95% CI: 0.08-0.28] per 10,000 births) [22] and in
France (0.34 [95% CI: 0.2-0.5] cases per 10,000 births)
in 2007 [14].
Congenital toxoplasmosis may be characterized as a
low-incidence disease in Greece, but not of low import-
ance, due to its potentially severe complications. Epi-
demiological data for toxoplasmosis in general come
from scarce studies throughout the country. Seropreva-
lence of Toxoplasma infection in the general Greek
population ranges from 32.2% to 45% [23-25], whereas a
29.2% seroprevalence was reported in pregnant women
[26] and the seroconversion rate has been estimated to
be 3.3% [27]. Variations may be due to a number of rea-
sons, including varying eating habits in different areas,
different climatic conditions etc.Ten symptomatic CT cases at birth (47% of all con-
firmed and probable cases) were reported during the
study. Chorioretinitis was the most frequent manifest-
ation (50% of symptomatic cases). Although there is a
low incidence of primary maternal infection in Greece,
the uncertain benefit of prenatal screening to a small
number of women and children should not outweigh the
risk of side effects from invasive diagnosis and the
high cost of diagnostic methods and treatment. Studies
have shown that in the absence of prenatal treatment,
the frequency of chorioretinitis and cerebral lesions was
higher [28].
Geographical distribution of cases was variable. The
higher prevalence observed in the regions of Thessaly,
Macedonia and Attica may be due to different cli matic
characteristics of those areas or different dietary habits
of the resident populations. Further studies are needed
to elucidate the reasons for such a variable geographical
distribution of CT cases.
The estimated lower birth prevalence by using the data
of the DSN compared to those in other countries may
be attributed to different methodological approaches
and the use of different case definitions and classifica-
tion systems at the time of the study in each country.
Additionally, epidemiological results for other countries
are based on screening programmes which have been
implemented and tested for years in contrast to the
results of GCPSU, which were based on an experimental
pilot surveillance system. This DSN study only detected
lesions evident at birth. However, the burden of CT
would be better assessed by long-term follow-up of
cases, as congenitally infected newborns that are asymp-
tomatic at birth are at risk of developing ocular lesions
during childhood and adolescence, leading to visual im-
pairment. Thus, greater cohorts and long-term follow-
up are required to confirm the encouraging results of
the present study.Conclusion
A dedicated surveillance network facilitated by GCPSU
proved to be a sensitive and cost-effective means for
capturing newly diagnosed cases of CT. The results pre-
sented here should encourage clinicians of different spe-
cialties to actively participate in this and other study
groups, allowing for the active surveillance of other rare
diseases as well.Abbreviations
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